The mutation frequency of RB1 in our cohort of NSCLC was 8.2%, which is consistent with prior reports and the TCGA database.5 The baseline characteristics (Table 1) of RB1 mutant compared to RB1 wt patients were well balanced between the 2 groups, except for a higher number of stage 3 patients in the RB1 mutant NSCLC group. Here, RB1 is linked to non-small cell lung carcinoma.